The short answer: what actually determines suitability

Three things have to align before ChondroFiller injection becomes the right option: the grade and character of the cartilage damage, the mechanical condition of the joint, and the patient's underlying health. Having cartilage wear — even significant wear — is not on its own enough to confirm candidacy, and nor does it rule it out.

The reason each criterion matters comes down to how the treatment works. ChondroFiller is an acellular collagen scaffold; once placed under ultrasound guidance, it recruits the patient's own progenitor cells from the surrounding tissue to drive repair through a process called matrix-induced chondrogenesis. That process depends entirely on the local biological environment being capable of supporting it. A joint with advanced generalised degeneration, uncontrolled inflammation, or uncorrected mechanical loading problems cannot provide that environment, regardless of how the symptoms feel.

The practical implication is that self-assessment based on pain levels or scan reports alone is unreliable. Formal MRI characterisation of defect grade and size, weight-bearing X-rays, and clinical scoring are what determine whether a patient falls within the treatable window.

The cartilage damage profile that fits

Grade III and Grade IV on the Outerbridge (ICRS) scale — partial- to full-thickness cartilage loss — mark the formal threshold at which ChondroFiller injection is indicated. Below that level, the remaining cartilage may not require scaffold support; at the other extreme, where degeneration has become generalised rather than focal, the biological environment the scaffold depends on is no longer reliably intact.

The character of the damage matters as much as the grade. The treatment works best where the loss is focal and contained — a discrete patch arising from a specific cause rather than diffuse wear across the whole joint surface. Post-traumatic chondral lesions, osteochondritis dissecans (OCD), cartilage damage associated with femoroacetabular impingement (FAI), and wear following a meniscal tear or ligament injury are considered particularly appropriate presentations, provided the surrounding joint structure remains intact.

On defect size: the ultrasound-guided injection pathway carries no hard upper size limit, as the liquid scaffold can coat the full articular surface. The 6 cm² ceiling cited in clinical literature applies to the surgical implantation route — a distinct pathway that should not be conflated with the current injection service.

The evidence base spans multiple joints. Knee and hip carry the most published data: a 17-patient knee cohort and a 26-patient hip cohort followed to 60 months both demonstrated meaningful functional gains when candidacy criteria were met, with 17 of 21 hip patients achieving good or excellent results. A 2025 wrist study demonstrated technical feasibility in smaller joints. Patient ages across these cohorts range broadly from the 30s into the 70s, reflecting that age alone is not the determining variable.

Joint and systemic prerequisites

Beyond the cartilage damage profile, two further layers of assessment serve as the stable platform on which scaffold biology must function: joint-level structural status and the patient's capacity to heal.

Weight-bearing X-rays address the first directly. Preserved joint space — surfaces that are not in direct contact — confirms that sufficient biological substrate remains for scaffold integration. Once that space is fully lost, the cell-recruitment process ChondroFiller relies on has no viable environment to work in; this is not a finding that injection can address.

Joint mechanics must also be stable. Ligament laxity, significant malalignment, or a meniscal deficit actively driving wear each alter loading in ways the scaffold cannot compensate for. These are correctable problems rather than permanent exclusions, but they need to be resolved before treatment proceeds.

Patients are expected to have reached the practical limit of conservative care before injection is considered — an adequate course of physiotherapy, activity modification, and analgesia should have been trialled without achieving satisfactory relief.

Systemic health factors require case-by-case clinical weighing rather than blanket rules. Immunosuppression, poorly controlled diabetes, and active anticoagulant therapy do not automatically disqualify a patient, but all can impair the endogenous repair response the scaffold depends on, so medication history and general health are reviewed as standard at the pre-treatment consultation.

A 2024 biomechanical finding adds a practical note for active and working-age patients: the scaffold carries some initial instability, making restricted weight-bearing in the early post-procedure period clinically appropriate. This is a manageable recovery consideration rather than a prohibitive one, but it is worth factoring into lifestyle planning before committing to the pathway.

Clear contraindications

Some presentations fall clearly outside what ChondroFiller can safely or effectively address. Recognising them avoids misplaced expectation.

Advanced generalised osteoarthritis ('bone-on-bone'). This is the most frequently misunderstood boundary. Once degeneration has spread across the joint surface and joint space is lost on X-ray, the biological environment the scaffold depends on for cell recruitment no longer exists. The hip cohort data discussed in the previous section illustrates this directly: patients graded Tönnis 2–3 at baseline achieved poor results, confirming that widespread background joint degeneration is a decisive negative prognostic factor — not a presentation the injectable scaffold can reverse.

Inflammatory joint disease. Rheumatoid arthritis, psoriatic arthritis, and gout each produce immune-mediated synovial inflammation that chemically disrupts scaffold integration into host tissue — the inflammatory milieu undermines the repair process the treatment depends on.

Active joint or systemic infection. Introducing a biologic device into an infected environment carries significant clinical risk; active infection at any level is an absolute bar.

Known allergy to Type I collagen or rat proteins. ChondroFiller is derived from veterinary-monitored rat-sourced Type I collagen, making an established allergy to either a direct contraindication.

Pregnancy and breastfeeding. No safety data exist for injectable biologic therapies in this population.

Mechanical issues that must be corrected first

The distinction worth making explicit — because it changes the conversation entirely — is between 'not yet' and 'never'.

Ligament instability, significant malalignment, and a meniscal deficit driving the wear are mechanical problems, not permanent verdicts. As noted above, each one creates loading conditions that would work against the scaffold during integration. But all three are, in principle, correctable: ligament reconstruction, osteotomy to address alignment, or meniscal repair or replacement can each restore the stable joint platform the treatment requires. Once that correction has been made and the joint has settled, a patient who was previously unsuitable may meet the criteria for ChondroFiller injection at a staged second step.

For patients in this category, the clinician's task is to identify whether the mechanical problem is addressable, in what sequence, and over what timeframe — not to close the conversation at the first assessment. That staging plan is individual, and the outcome of the mechanical correction itself will determine whether injection remains the right next move.

How suitability is formally assessed

Reaching a confident answer on suitability requires three converging sources of information.

MRI is the primary imaging tool. It characterises defect grade, size, and the quality of the surrounding cartilage — all of which bear directly on whether an injectable collagen scaffold can integrate and recruit the patient's own repair cells effectively. A defect that appears symptomatic on clinical examination may look very different in terms of depth and boundary definition once the MRI is reviewed.

Weight-bearing X-rays confirm that joint space is preserved and that the joint falls outside the advanced degenerative range outlined in the preceding sections.

Clinical scoring — VAS for pain intensity, and either IKDC or WOMAC for functional status — establishes the baseline from which any meaningful response to treatment will be measured. Patients with moderate pain and preserved joint space tend to show the clearest functional gains in published series.

None of these elements is sufficient in isolation. The imaging defines the anatomy; the scoring anchors the clinical picture; the consultation synthesises both with the patient's wider health profile and treatment history. Suitability is never self-determined, and the workup itself is designed to give patients and clinicians a clear, evidence-based answer rather than an ambiguous one.

Professor Paul Y. F. Lee leads specialist cartilage assessment at London Cartilage Clinic on Harley Street, and an initial consultation to discuss whether ChondroFiller injection is appropriate for a specific defect and joint can be arranged through londoncartilage.com.

1. [1] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002